IBRX News and Press, ImmunityBio Inc.

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ImmunityBio, Inc. (NasdaqGS: IBRX). On May 11, 2023, the Company disclosed that it had receiv...

2024-07-17 06:30:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Discovering and developing a cancer drug that can treat many types of the disease can be extremely lucrative. Consider that one such drug, Merck’s (NYSE: MRK ) Keytruda, ...

2024-07-09 10:10:00 ET July 9, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Tech, Biotech, Cleantech and Mining Sectors. The newest tech company is involved in AI and Blo...

2024-07-09 09:19:07 ET Summary CG Oncology's cretostimogene shows high potential to disrupt the NMIBC market with promising efficacy and safety data. The company is initially targeting high-risk NMIBC patients who no longer respond to the BCG vaccine, but intermediate-risk patient...

2024-07-08 23:23:13 ET Summary ImmunityBio has seen success with its first drug approval for bladder cancer, Anktiva, and positive results in lung cancer trials. Financially, the company has a weak cash position but the potential for significant sales with Anktiva, leading to a $4...

2024-07-07 01:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-25 15:44:03 ET Summary IBRX has a short interest % of the float of 33%, superior to GME at 21%. Investors should keep an eye on it for short squeeze-fueled volatility. IBRX has positive catalysts on the horizon, such as the commercialization of Anktiva for bladder cancer a...

2024-06-20 12:28:47 ET More on ImmunityBio ImmunityBio: Anktiva's Launch Demands A Reassessment ImmunityBio: Anktiva Approval Opens Up A World Of Possibilities, Risks And Potential Gains ImmunityBio: FDA Approval Gets Ball Rolling Towards Next Set Of Indications ...

Multiple patients treated across the U.S. with ANKTIVA less than eight weeks after FDA approval of first-in-class cytokine immunotherapy for BCG unresponsive non-muscle invasive bladder cancer ANKTIVA launch initiates the next era of immunotherapy beyond checkpoint inhibitors that is based on...

2024-06-07 10:10:00 ET June 7, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform, releases the second of a two-part series looking at news and developments for the treatment of viruses, featuring Aethlon Medical, Inc. (Nasdaq: AEMD ), a medical the...